-+ 0.00%
-+ 0.00%
-+ 0.00%

WHO assigns proposed INN vanexin to Annexin Pharmaceuticals’ ANXV candidate

PUBT·08/20/2026 06:35:16
Listen to the news
WHO assigns proposed INN vanexin to Annexin Pharmaceuticals’ ANXV candidate
  • Annexin Pharmaceuticals received WHO’s proposed International Nonproprietary Name “vanexin” for its lead drug candidate ANXV.
  • The move supports regulatory positioning for the recombinant Annexin A5 program, currently in Phase 2a ophthalmology studies.
  • Vanexin is expected to become the recommended INN later this year if no objections emerge in the WHO process.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Annexin Pharmaceuticals AB (publ) published the original content used to generate this news brief on August 20, 2026, and is solely responsible for the information contained therein.